

Patricia Brubaker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1393406/publications.pdf>

Version: 2024-02-01

194
papers

13,794
citations

14655

66
h-index

22166

113
g-index

197
all docs

197
docs citations

197
times ranked

8299
citing authors

#	ARTICLE	IF	CITATIONS
1	Metabolic homeostasis: itâ€™s all in the timing. <i>Endocrinology</i> , 2022, 163, .	2.8	5
2	Complementary and antagonistic effects of combined glucagonâ€like peptideâ€2 and glucagonâ€like peptideâ€1 receptor agonist administration on parameters relevant to short bowel syndrome. <i>Journal of Parenteral and Enteral Nutrition</i> , 2022, 46, 1361-1370.	2.6	4
3	The intestine and the microbiota in maternal glucose homeostasis during pregnancy. <i>Journal of Endocrinology</i> , 2022, 253, R1-R19.	2.6	11
4	Glucagon-Like Peptide-2 Stimulates S-Phase Entry of Intestinal Lgr5+ Stem Cells. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 1829-1842.	4.5	11
5	Nobiletin ameliorates high fat-induced disruptions in rhythmic glucagon-like peptide-1 secretion. <i>Scientific Reports</i> , 2022, 12, 7271.	3.3	7
6	Inflaming the Clock: Effects of Interleukin 1 ^{Î²} on Circadian Rhythmicity of Pancreatic Î² Cells. <i>Endocrinology</i> , 2021, 162, .	2.8	0
7	L-cell Arntl is required for rhythmic glucagon-like peptide-1 secretion and maintenance of intestinal homeostasis. <i>Molecular Metabolism</i> , 2021, 54, 101340.	6.5	12
8	Effects of Obesogenic Feeding and Free Fatty Acids on Circadian Secretion of Metabolic Hormones: Implications for the Development of Type 2 Diabetes. <i>Cells</i> , 2021, 10, 2297.	4.1	9
9	Diurnal changes in the murine small intestine are disrupted by obesogenic Western Diet feeding and microbial dysbiosis. <i>Scientific Reports</i> , 2021, 11, 20571.	3.3	6
10	The core clock gene, Bmal1, and its downstream target, the SNARE regulatory protein secretagogin, are necessary for circadian secretion of glucagon-like peptide-1. <i>Molecular Metabolism</i> , 2020, 31, 124-137.	6.5	34
11	Durability of Linear Smallâ€Intestinal Growth Following Treatment Discontinuation of Longâ€Acting Glucagonâ€Like Peptide 2 (GLPâ€2) Analogues. <i>Journal of Parenteral and Enteral Nutrition</i> , 2020, 45, 1466-1474.	2.6	1
12	In the Shortâ€Term, Milk Fat Globule Epidermal Growth Factorâ€8 Causes Siteâ€Specific Intestinal Growth in Resected Piglets. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2020, 71, 543-549.	1.8	2
13	Circadian Rhythms and the Gastrointestinal Tract: Relationship to Metabolism and Gut Hormones. <i>Endocrinology</i> , 2020, 161, .	2.8	20
14	Circadian GLP-1 Secretion in Mice Is Dependent on the Intestinal Microbiome for Maintenance of Diurnal Metabolic Homeostasis. <i>Diabetes</i> , 2020, 69, 2589-2602.	0.6	33
15	Why Recycling Matters: Glucagon-Like Peptide-2 and the Regulation of Intestinal Sodium and Fluid Absorption. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3422-3424.	2.3	0
16	Dietary Cyanidin-3-Glucoside Attenuates High-Fat-Dietâ€Induced Body-Weight Gain and Impairment of Glucose Tolerance in Mice via Effects on the Hepatic Hormone FGF21. <i>Journal of Nutrition</i> , 2020, 150, 2101-2111.	2.9	15
17	Essential Role of Syntaxin-Binding Protein-1 in the Regulation of Glucagon-Like Peptide-1 Secretion. <i>Endocrinology</i> , 2020, 161, .	2.8	25
18	GLP-2, EGF, and the Intestinal Epithelial IGF-1 Receptor Interactions in the Regulation of Crypt Cell Proliferation. <i>Endocrinology</i> , 2020, 161, .	2.8	13

#	ARTICLE	IF	CITATIONS
19	Requirement for the intestinal epithelial insulin-like growth factor-1 receptor in the intestinal responses to glucagon-like peptide-2 and dietary fat. <i>FASEB Journal</i> , 2020, 34, 6628-6640.	0.5	6
20	Analysis of Western diet, palmitate and BMAL1 regulation of neuropeptide Y expression in the murine hypothalamus and BMAL1 knockout cell models. <i>Molecular and Cellular Endocrinology</i> , 2020, 507, 110773.	3.2	17
21	Site-Specific and Temporal Effects of Apraglutide, a Novel Long-Acting Glucagon-Like Peptide-2 Receptor Agonist, on Intestinal Growth in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 373, 347-352.	2.5	9
22	Novel Long-Acting GLP-2 Analogue, FE 203799 (Apraglutide), Enhances Adaptation and Linear Intestinal Growth in a Neonatal Piglet Model of Short Bowel Syndrome with Total Resection of the Ileum. <i>Journal of Parenteral and Enteral Nutrition</i> , 2019, 43, 891-898.	2.6	33
23	The roles of glucagon-like peptide-2 and the intestinal epithelial insulin-like growth factor-1 receptor in regulating microvillus length. <i>Scientific Reports</i> , 2019, 9, 13010.	3.3	15
24	SUN-LB018 Role of BMAL1 in Western Diet-Induced Disruption of Circadian Hypothalamic Feeding Neuropeptides. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	0
25	The Cardiac Glucagonlike Peptide-1 Receptor: Whither Art Thou?. <i>Endocrinology</i> , 2018, 159, 1842-1843.	2.8	0
26	Suppression of circadian secretion of glucagon-like peptide-1 by the saturated fatty acid, palmitate. <i>Acta Physiologica</i> , 2018, 222, e13007.	3.8	34
27	Insulin-like growth factor-binding protein-4 inhibits epithelial growth and proliferation in the rodent intestine. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, G206-G219.	3.4	7
28	Glucagon-Like Peptide-2 and the Regulation of Intestinal Growth and Function. , 2018, 8, 1185-1210.		76
29	Linking the Gut Microbiome to Metabolism Through Endocrine Hormones. <i>Endocrinology</i> , 2018, 159, 2978-2979.	2.8	9
30	Synergy of glucagon-like peptide-2 and epidermal growth factor coadministration on intestinal adaptation in neonatal piglets with short bowel syndrome. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 312, G390-G404.	3.4	27
31	Comment on Ussar et al. Regulation of Glucose Uptake and Enteroendocrine Function by the Intestinal Epithelial Insulin Receptor. <i>Diabetes</i> 2017;66:886-896. <i>Diabetes</i> , 2017, 66, e5-e5.	0.6	1
32	The SNARE Protein Syntaxin-1a Plays an Essential Role in Biphasic Exocytosis of the Incretin Hormone Glucagon-Like Peptide 1. <i>Diabetes</i> , 2017, 66, 2327-2338.	0.6	30
33	Quantitative Proteomics of Intestinal Mucosa From Male Mice Lacking Intestinal Epithelial Insulin Receptors. <i>Endocrinology</i> , 2017, 158, 2470-2485.	2.8	5
34	Elucidating the Biological Roles of Insulin and Its Receptor in Murine Intestinal Growth and Function. <i>Endocrinology</i> , 2017, 158, 2453-2469.	2.8	6
35	Species-Dependent Mechanisms Regulating Glucose-Dependent GLP-1 Secretion?. <i>Diabetes</i> , 2017, 66, 2063-2065.	0.6	3
36	Glucagon-Like Peptide-2 Requires a Full Complement of Bmi-1 for Its Proliferative Effects in the Murine Small Intestine. <i>Endocrinology</i> , 2016, 157, 2660-2670.	2.8	8

#	ARTICLE	IF	CITATIONS
37	Glucagon-like peptide-1: The missing link in the metabolic clock?. Journal of Diabetes Investigation, 2016, 7, 70-75.	2.4	23
38	Current and potential therapeutic targets of glucagon-like peptide-2. Current Opinion in Pharmacology, 2016, 31, 13-18.	3.5	22
39	The Endocrine Society Centennial: Cleavage Matters. Endocrinology, 2016, 157, 4091-4093.	2.8	0
40	Short-term sleep deprivation with nocturnal light exposure alters time-dependent glucagon-like peptide-1 and insulin secretion in male volunteers. American Journal of Physiology - Endocrinology and Metabolism, 2016, 310, E41-E50.	3.5	79
41	On the horizon: trophic peptide growth factors as therapy for neonatal short bowel syndrome. Expert Opinion on Therapeutic Targets, 2016, 20, 819-830.	3.4	8
42	High-Fat Diet and Palmitate Alter the Rhythmic Secretion of Glucagon-Like Peptide-1 by the Rodent L-cell. Endocrinology, 2016, 157, 586-599.	2.8	51
43	Diabetes, trekking and high altitude: recognizing and preparing for the risks. Diabetic Medicine, 2015, 32, 1425-1437.	2.3	20
44	GLP-1R Agonists Promote Normal and Neoplastic Intestinal Growth through Mechanisms Requiring Fgf7. Cell Metabolism, 2015, 21, 379-391.	16.2	94
45	Chronic Exposure to TNF- α Impairs Secretion of Glucagon-Like Peptide-1. Endocrinology, 2015, 156, 3950-3960.	2.8	36
46	IGF Binding Protein-4 is Required for the Growth Effects of Glucagon-Like Peptide-2 in Murine Intestine. Endocrinology, 2015, 156, 429-436.	2.8	18
47	Chrelin Is a Novel Regulator of GLP-1 Secretion. Diabetes, 2015, 64, 1513-1521.	0.6	96
48	Murine GLUTag Cells. , 2015, , 229-238.		1
49	Combined Glucagon-like Peptide-2 and Epidermal Growth Factor Therapy Maximally Stimulates Adaptation in Neonatal Intestinal Failure without Ileum. FASEB Journal, 2015, 29, 265.3.	0.5	0
50	Exogenous glucagon-like peptide-2 improves outcomes of intestinal adaptation in a distal-intestinal resection neonatal piglet model of short bowel syndrome. Pediatric Research, 2014, 76, 370-377.	2.3	31
51	R-spondin1 Deficiency Enhances β -Cell Neogenesis in a Murine Model of Diabetes. Pancreas, 2014, 43, 93-102.	1.1	4
52	Gut Hormones Fulfill Their Destiny: From Basic Physiology to the Clinic. Annual Review of Physiology, 2014, 76, 515-517.	18.1	4
53	Role of vesicle-associated membrane protein 2 in exocytosis of glucagon-like peptide-1 from the murine intestinal L cell. Diabetologia, 2014, 57, 809-818.	6.3	26
54	Circadian Secretion of the Intestinal Hormone GLP-1 by the Rodent L Cell. Diabetes, 2014, 63, 3674-3685.	0.6	104

#	ARTICLE	IF	CITATIONS
55	The Intestinal Epithelial Insulin-Like Growth Factor-1 Receptor Links Glucagon-Like Peptide-2 Action to Gut Barrier Function. <i>Endocrinology</i> , 2014, 155, 370-379.	2.8	79
56	Effects of prolonged exendin-4 administration on hypothalamic-pituitary-adrenal axis activity and water balance. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2013, 304, E1105-E1117.	3.5	22
57	Role of fatty acid transport protein 4 in oleic acid-induced glucagon-like peptide-1 secretion from murine intestinal L cells. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2012, 303, E899-E907.	3.5	40
58	Glucagon-like peptide-2 increases dysplasia in rodent models of colon cancer. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 302, G840-G849.	3.4	40
59	A Beautiful Cell (or Two or Three?). <i>Endocrinology</i> , 2012, 153, 2945-2948.	2.8	20
60	Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2012, 9, 705-715.	17.8	34
61	Novel Biological Action of the Dipeptidylpeptidase-IV Inhibitor, Sitagliptin, as a Glucagon-Like Peptide-1 Secretagogue. <i>Endocrinology</i> , 2012, 153, 564-573.	2.8	40
62	Loss of Glucagon-Like Peptide-2-Induced Proliferation Following Intestinal Epithelial Insulin-Like Growth Factor-1 Receptor Deletion. <i>Gastroenterology</i> , 2011, 141, 2166-2175.e7.	1.3	74
63	R-spondin1 deficiency in mice improves glycaemic control in association with increased beta cell mass. <i>Diabetologia</i> , 2011, 54, 1726-1734.	6.3	5
64	The "cryptic" mechanism of action of glucagon-like peptide-2. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 301, G1-G8.	3.4	124
65	Mechanisms Underlying Metformin-Induced Secretion of Glucagon-Like Peptide-1 from the Intestinal L Cell. <i>Endocrinology</i> , 2011, 152, 4610-4619.	2.8	139
66	Essential Role for Protein Kinase C η in Oleic Acid-Induced Glucagon-Like Peptide-1 Secretion in Vivo in the Rat. <i>Endocrinology</i> , 2011, 152, 1244-1252.	2.8	39
67	Mechanism of Action of Glucagon-Like Peptide-2 to Increase IGF-I mRNA in Intestinal Subepithelial Fibroblasts. <i>Endocrinology</i> , 2011, 152, 436-446.	2.8	51
68	R-spondin-1 Is a Novel β -Cell Growth Factor and Insulin Secretagogue. <i>Journal of Biological Chemistry</i> , 2010, 285, 21292-21302.	3.4	28
69	From Enteroglucagon to the Glucagon-Like Peptides, GLP-1 and GLP-2. <i>Canadian Journal of Diabetes</i> , 2010, 34, 190-192.	0.8	0
70	Minireview: Update on Incretin Biology: Focus on Glucagon-Like Peptide-1. <i>Endocrinology</i> , 2010, 151, 1984-1989.	2.8	105
71	GPR119 Is Essential for Oleoylethanolamide-Induced Glucagon-Like Peptide-1 Secretion From the Intestinal Enteroendocrine L-Cell. <i>Diabetes</i> , 2009, 58, 1058-1066.	0.6	319
72	The Rho Guanosine 5'-Triphosphatase, Cell Division Cycle 42, Is Required for Insulin-Induced Actin Remodeling and Glucagon-Like Peptide-1 Secretion in the Intestinal Endocrine L Cell. <i>Endocrinology</i> , 2009, 150, 5249-5261.	2.8	38

#	ARTICLE	IF	CITATIONS
73	Insulin Regulates Glucagon-Like Peptide-1 Secretion from the Enteroendocrine L Cell. <i>Endocrinology</i> , 2009, 150, 580-591.	2.8	148
74	Epac is involved in cAMP-stimulated proglucagon expression and hormone production but not hormone secretion in pancreatic $\hat{I}\pm$ - and intestinal L-cell lines. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2009, 296, E174-E181.	3.5	32
75	Carcinogenic Effects of Exogenous and Endogenous Glucagon-Like Peptide-2 in Azoxymethane-Treated Mice. <i>Endocrinology</i> , 2009, 150, 4033-4043.	2.8	52
76	Glucagon-Like Peptide-2 Increases Intestinal Lipid Absorption and Chylomicron Production via CD36. <i>Gastroenterology</i> , 2009, 137, 997-1005.e4.	1.3	168
77	Life in the crypt: A role for glucagon-like peptide-2?. <i>Molecular and Cellular Endocrinology</i> , 2008, 288, 63-70.	3.2	25
78	Glucagon-Like Peptide-2 Activates \hat{I}^2 -Catenin Signaling in the Mouse Intestinal Crypt: Role of Insulin-Like Growth Factor-I. <i>Endocrinology</i> , 2008, 149, 291-301.	2.8	64
79	GPR119: "Double-Dipping" for Better Glycemic Control. <i>Endocrinology</i> , 2008, 149, 2035-2037.	2.8	49
80	Cross Talk between the Insulin and Wnt Signaling Pathways: Evidence from Intestinal Endocrine L Cells. <i>Endocrinology</i> , 2008, 149, 2341-2351.	2.8	127
81	Role of glial cell-line derived neurotrophic factor family receptor $\hat{I}\pm 2$ in the actions of the glucagon-like peptides on the murine intestine. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 293, G461-G468.	3.4	24
82	Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 293, E460-E465.	3.5	136
83	Role of phosphatidylinositol-3 kinase- \hat{I}^3 in the actions of glucagon-like peptide-2 on the murine small intestine. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 292, E1599-E1606.	3.5	10
84	Incretin-based therapies: mimetics versus protease inhibitors. <i>Trends in Endocrinology and Metabolism</i> , 2007, 18, 240-245.	7.1	44
85	Protein Kinase C \hat{I}^{η} Is Required for Oleic Acid-Induced Secretion of Glucagon-Like Peptide-1 by Intestinal Endocrine L Cells. <i>Endocrinology</i> , 2007, 148, 1089-1098.	2.8	89
86	A Mathematical Model of the Oral Glucose Tolerance Test Illustrating the Effects of the Incretins. <i>Annals of Biomedical Engineering</i> , 2007, 35, 1286-1300.	2.5	32
87	The Essential Role of Insulin-Like Growth Factor-1 in the Intestinal Tropic Effects of Glucagon-Like Peptide-2 in Mice. <i>Gastroenterology</i> , 2006, 131, 589-605.	1.3	161
88	The Glucagon-Like Peptides: Pleiotropic Regulators of Nutrient Homeostasis. <i>Annals of the New York Academy of Sciences</i> , 2006, 1070, 10-26.	3.8	85
89	Role of Phosphatidylinositol 3-Kinase- \hat{I}^3 in the \hat{I}^2 -Cell: Interactions with Glucagon-Like Peptide-1. <i>Endocrinology</i> , 2006, 147, 3318-3325.	2.8	32
90	From cradle to grave: pancreatic beta-cell mass and glucagon-like peptide-1. <i>Minerva Endocrinologica</i> , 2006, 31, 107-24.	1.8	4

#	ARTICLE	IF	CITATIONS
91	Glucagon-like peptide 2: an update. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2005, 12, 63-71.	0.6	5
92	Peripheral Exendin-4 and Peptide YY36 Synergistically Reduce Food Intake through Different Mechanisms in Mice. <i>Endocrinology</i> , 2005, 146, 3748-3756.	2.8	273
93	PKA independent and cell type specific activation of the expression of caudal homeobox gene Cdx-2 by cyclic AMP. <i>FEBS Journal</i> , 2005, 272, 2746-2759.	4.7	33
94	Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B. <i>Diabetologia</i> , 2005, 48, 1339-1349.	6.3	186
95	Adventure Travel and Type 1 Diabetes: The complicating effects of high altitude. <i>Diabetes Care</i> , 2005, 28, 2563-2572.	8.6	42
96	TCF-4 Mediates Cell Type-specific Regulation of Proglucagon Gene Expression by β -Catenin and Glycogen Synthase Kinase-3 β . <i>Journal of Biological Chemistry</i> , 2005, 280, 1457-1464.	3.4	359
97	β -Cell Pdx1 Expression Is Essential for the Glucoregulatory, Proliferative, and Cytoprotective Actions of Glucagon-Like Peptide-1. <i>Diabetes</i> , 2005, 54, 482-491.	0.6	213
98	Mucosal Adaptation to Enteral Nutrients is Dependent on the Physiologic Actions of Glucagon-Like Peptide-2 in Mice. <i>Gastroenterology</i> , 2005, 128, 1340-1353.	1.3	118
99	Minireview: Glucagon-Like Peptides Regulate Cell Proliferation and Apoptosis in the Pancreas, Gut, and Central Nervous System. <i>Endocrinology</i> , 2004, 145, 2653-2659.	2.8	486
100	Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. <i>Diabetologia</i> , 2004, 47, 478-487.	6.3	184
101	Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2. <i>Canadian Journal of Physiology and Pharmacology</i> , 2003, 81, 1005-1012.	1.4	183
102	Muscarinic Receptors Control Glucagon-Like Peptide 1 Secretion by Human Endocrine L Cells. <i>Endocrinology</i> , 2003, 144, 3244-3250.	2.8	112
103	Role of Leptin in the Regulation of Glucagon-Like Peptide-1 Secretion. <i>Diabetes</i> , 2003, 52, 252-259.	0.6	228
104	Glucagon-Like Peptide-2 and Common Therapeutics in a Murine Model of Ulcerative Colitis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 306, 347-354.	2.5	72
105	Pax-6 Activates Endogenous Proglucagon Gene Expression in the Rodent Gastrointestinal Epithelium. <i>Diabetes</i> , 2003, 52, 425-433.	0.6	45
106	Transcriptional Activation of the Proglucagon Gene by Lithium and β -Catenin in Intestinal Endocrine L Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 1380-1387.	3.4	71
107	Glucagon-Like Peptide-2 Receptor Activation in the Rat Intestinal Mucosa. <i>Endocrinology</i> , 2003, 144, 4385-4392.	2.8	61
108	Glucagon-like Peptides: GLP-1 and GLP-2. , 2003, , 55-62.		4

#	ARTICLE	IF	CITATIONS
109	Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. <i>Journal of Clinical Investigation</i> , 2003, 112, 1550-1560.	8.2	276
110	Foxa3 (HNF-3 β) binds to and activates the rat proglucagon gene promoter but is not essential for proglucagon gene expression. <i>Biochemical Journal</i> , 2002, 366, 633-641.	3.7	26
111	Cellular Specificity of Proexendin-4 Processing in Mammalian Cells in Vitro and in Vivo. <i>Endocrinology</i> , 2002, 143, 3464-3471.	2.8	3
112	Muscarinic Receptors Control Postprandial Release of Glucagon-Like Peptide-1: In Vivo and in Vitro Studies in Rats. <i>Endocrinology</i> , 2002, 143, 2420-2426.	2.8	124
113	Prolonged Gastrointestinal Transit in a Patient with a Glucagon-Like Peptide (GLP)-1- and -2-Producing Neuroendocrine Tumor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3078-3083.	3.6	34
114	Structure-Function of the Glucagon Receptor Family of G Protein-Coupled Receptors: The Glucagon, GIP, GLP-1, and GLP-2 Receptors. <i>Receptors and Channels</i> , 2002, 8, 179-188.	1.1	55
115	Elevated Glucagon-Like Peptide-1-(7 \rightarrow 36)-Amide, but Not Glucose, Associated with Hyperinsulinemic Compensation for Fat Feeding. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 5191-5198.	3.6	35
116	Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. <i>Diabetologia</i> , 2002, 45, 1263-1273.	6.3	297
117	Structure-Function of the Glucagon Receptor Family of G Protein-Coupled Receptors: The Glucagon, GIP, GLP-1, and GLP-2 Receptors. <i>Receptors and Channels</i> , 2002, 8, 179-188.	1.1	122
118	Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. <i>Receptors and Channels</i> , 2002, 8, 179-88.	1.1	49
119	Biological Activities of Glucagon-Like Peptide-1 Analogues in Vitro and in Vivo. <i>Biochemistry</i> , 2001, 40, 2860-2869.	2.5	97
120	A Glucagon-Like Peptide-1 Receptor Agonist and an Antagonist Modify Macronutrient Selection by Rats. <i>Journal of Nutrition</i> , 2001, 131, 2164-2170.	2.9	46
121	Monounsaturated Fatty Acid Diets Improve Glycemic Tolerance through Increased Secretion of Glucagon-Like Peptide-1*. <i>Endocrinology</i> , 2001, 142, 1148-1155.	2.8	135
122	Coregulation of Glucagon-Like Peptide-1 Synthesis with Proglucagon and Prohormone Convertase 1 Gene Expression in Enteroendocrine GLUTag Cells**This work was supported by operating grants (to) Tj ETQq0 0 0,rgBT /Overlock 10 Tf <i>Endocrinology</i> , 2001, 142, 37-42.	2.8	25
123	Therapeutic potential of the intestinotropic hormone, glucagon-like peptide-2. <i>Annals of Medicine</i> , 2001, 33, 229-235.	3.8	20
124	Coregulation of Glucagon-Like Peptide-1 Synthesis with Proglucagon and Prohormone Convertase 1 Gene Expression in Enteroendocrine GLUTag Cells. <i>Endocrinology</i> , 2001, 142, 37-42.	2.8	8
125	Monounsaturated Fatty Acid Diets Improve Glycemic Tolerance through Increased Secretion of Glucagon-Like Peptide-1. <i>Endocrinology</i> , 2001, 142, 1148-1155.	2.8	34
126	Oral delivery of glucagon-like peptide-1 in a modified polymer preparation normalizes basal glycaemia in diabetic db / db mice. <i>Diabetologia</i> , 2000, 43, 1319-1328.	6.3	46

#	ARTICLE	IF	CITATIONS
127	Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2000, 278, R1057-R1063.	1.8	79
128	Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats. American Journal of Physiology - Endocrinology and Metabolism, 2000, 278, E134-E139.	3.5	86
129	Ontogeny of the Glucagon-Like Peptide-2 Receptor Axis in the Developing Rat Intestine TM This work was supported in part by operating grants from the Medical Research Council (to D.J.D. and P.L.B.), the Crohn's and Colitis Foundation of Canada (to P.L.B.), and the Ontario Research and Development Challenge Fund (to D.J.D.). GLP-2 is the subject of a licensing agreement between Toronto General Hospital, the University of Toronto, D.J.D., and NPS Allelix Corp. Endocrinology, 2000, 141, 4194-4201.	2.8	71
130	Sustained Expression of Exendin-4 Does Not Perturb Glucose Homeostasis, β -Cell Mass, or Food Intake in Metallothionein-Preproexendin Transgenic Mice. Journal of Biological Chemistry, 2000, 275, 34471-34477.	3.4	34
131	Structural Determinants for Activity of Glucagon-like Peptide-2. Biochemistry, 2000, 39, 8888-8894.	2.5	60
132	Regulation of pancreatic PC1 and PC2 associated with increased glucagon-like peptide 1 in diabetic rats. Journal of Clinical Investigation, 2000, 105, 955-965.	8.2	142
133	Ontogeny of the Glucagon-Like Peptide-2 Receptor Axis in the Developing Rat Intestine. Endocrinology, 2000, 141, 4194-4201.	2.8	18
134	Human [Gly ²]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. American Journal of Physiology - Renal Physiology, 1999, 276, G79-G91.	3.4	91
135	Role of the Vagus Nerve in Mediating Proximal Nutrient-Induced Glucagon-Like Peptide-1 Secretion*. Endocrinology, 1999, 140, 1687-1694.	2.8	393
136	Biologic Properties and Therapeutic Potential of Glucagon-like Peptide-2. Journal of Parenteral and Enteral Nutrition, 1999, 23, S98-100.	2.6	22
137	Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs. Diabetes, 1999, 48, 1045-1053.	0.6	97
138	Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans. Gastroenterology, 1999, 117, 99-105.	1.3	181
139	Role of the Vagus Nerve in Mediating Proximal Nutrient-Induced Glucagon-Like Peptide-1 Secretion. Endocrinology, 1999, 140, 1687-1694.	2.8	99
140	Intestinal Proglucagon-Derived Peptides. , 1999, , 493-514.		0
141	Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling.. Diabetes, 1998, 47, 632-639.	0.6	111
142	Regulation of Glucagon-Like Peptide-1 Synthesis and Secretion in the GLUTag Enteroendocrine Cell Line1. Endocrinology, 1998, 139, 4108-4114.	2.8	144
143	Proglucagon Processing in an Islet Cell Line: Effects of PC1 Overexpression and PC2 Depletion1. Endocrinology, 1998, 139, 1630-1637.	2.8	35
144	Nutrient and Peptide Regulation of Somatostatin-28 Secretion from Intestinal Cultures ¹ . Endocrinology, 1998, 139, 148-155.	2.8	10

#	ARTICLE	IF	CITATIONS
145	Circulating and Tissue Forms of the Intestinal Growth Factor, Glucagon-Like Peptide-2*. <i>Endocrinology</i> , 1997, 138, 4837-4843.	2.8	118
146	The <i>Xenopus</i> proglucagon gene encodes novel GLP-1-like peptides with insulinotropic properties. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 7915-7920.	7.1	72
147	Intestinal growth is associated with elevated levels of glucagon-like peptide 2 in diabetic rats. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1997, 273, E815-E820.	3.5	37
148	Release of GLP-1 into the Circulation. <i>Frontiers in Diabetes</i> , 1997, 13, 65-84.	0.4	3
149	Intestinal response to growth factors administered alone or in combination with human [Gly ²]glucagon-like peptide 2. <i>American Journal of Physiology - Renal Physiology</i> , 1997, 273, G1252-G1262.	3.4	62
150	Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1997, 272, E1050-E1058.	3.5	133
151	Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1997, 273, E77-E84.	3.5	154
152	Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. <i>Nature Biotechnology</i> , 1997, 15, 673-677.	17.5	243
153	Truncated and full-length glucagon-like peptide-1 (GLP-1) differentially stimulate intestinal somatostatin release. <i>Endocrine</i> , 1997, 6, 91-95.	2.2	26
154	Proglucagon processing in islet and intestinal cell lines. <i>Regulatory Peptides</i> , 1996, 62, 29-35.	1.9	70
155	Inhibition of protein kinase A α -Induced glucagon synthesis and secretion by glucose. <i>Metabolism: Clinical and Experimental</i> , 1996, 45, 347-350.	3.4	2
156	Role of prohormone convertases in the tissue-specific processing of proglucagon.. <i>Molecular Endocrinology</i> , 1996, 10, 342-355.	3.7	191
157	Induction of intestinal epithelial proliferation by glucagon-like peptide 2.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 7911-7916.	7.1	777
158	Glucose intolerance but normal satiety in mice with a null mutation in the glucagon α -like peptide 1 receptor gene. <i>Nature Medicine</i> , 1996, 2, 1254-1258.	30.7	710
159	Gastrin-releasing peptide is a novel mediator of proximal nutrient-induced proglucagon-derived peptide secretion from the distal gut.. <i>Endocrinology</i> , 1996, 137, 2383-2388.	2.8	92
160	Gastrin-releasing peptide is a novel mediator of proximal nutrient- induced proglucagon-derived peptide secretion from the distal gut. <i>Endocrinology</i> , 1996, 137, 2383-2388.	2.8	27
161	Synthesis and secretion of glucagon-like peptide-1 by fetal rat intestinal cells in culture. <i>Endocrine</i> , 1995, 3, 499-503.	2.2	31
162	Mechanism of action of glucagon-like peptide-1 α -36NH ₂ in isolated rat pancreatic islets and abrogation of its effects in long-term incubations. <i>Endocrine</i> , 1995, 3, 795-799.	2.2	4

#	ARTICLE	IF	CITATIONS
163	Stereospecific effects of fatty acids on proglucagon-derived peptide secretion in fetal rat intestinal cultures.. <i>Endocrinology</i> , 1995, 136, 5593-5599.	2.8	100
164	Role of glutamate in regulating hypothalamic proglucagon-derived peptide secretion in vitro. <i>Life Sciences</i> , 1995, 56, 1325-1331.	4.3	0
165	Activation of proglucagon gene transcription by protein kinase-A in a novel mouse enteroendocrine cell line.. <i>Molecular Endocrinology</i> , 1994, 8, 1646-1655.	3.7	229
166	Increase in somatostatin to glucagon ratio in islets of alloxan-diabetic dogs: effect of insulin-induced euglycemia. <i>Canadian Journal of Physiology and Pharmacology</i> , 1993, 71, 512-517.	1.4	7
167	Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop.. <i>Endocrinology</i> , 1993, 133, 233-240.	2.8	225
168	Calcitonin gene-related peptide-I preferentially stimulates secretion of somatostatin from intestinal cultures.. <i>Endocrinology</i> , 1993, 133, 2833-2837.	2.8	7
169	Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. <i>Endocrinology</i> , 1993, 133, 233-240.	2.8	73
170	Calcitonin gene-related peptide-I preferentially stimulates secretion of somatostatin from intestinal cultures. <i>Endocrinology</i> , 1993, 133, 2833-2837.	2.8	4
171	Control of Proglucagon-Derived Peptide Synthesis and Secretion in Fetal Rat Hypothalamus. <i>Neuroendocrinology</i> , 1992, 56, 340-347.	2.5	5
172	Alterations in proglucagon processing and inhibition of proglucagon gene expression in transgenic mice which contain a chimeric proglucagon-SV40 T antigen gene. <i>Journal of Biological Chemistry</i> , 1992, 267, 20728-33.	3.4	27
173	Regulation of Intestinal Proglucagon- Derived Peptide Secretion by Intestinal Regulatory Peptides*. <i>Endocrinology</i> , 1991, 128, 3175-3182.	2.8	149
174	Failure of chronic hyperinsulinemia to suppress pancreatic glucagon in vivo in the rat. <i>Canadian Journal of Physiology and Pharmacology</i> , 1991, 69, 437-443.	1.4	7
175	Regulation of Peptide-YY Synthesis and Secretion in Fetal Rat Intestinal Cultures*. <i>Endocrinology</i> , 1991, 129, 3351-3358.	2.8	29
176	Secretion of Proglucagon-Derived Peptides in Response to Intestinal Luminal Nutrients*. <i>Endocrinology</i> , 1991, 128, 3169-3174.	2.8	132
177	Proglucagon-Derived Peptides in the Neuroendocrine System. <i>Advances in Experimental Medicine and Biology</i> , 1991, 291, 143-159.	1.6	1
178	Differential glucocorticoid regulation of glucagon gene expression in cell lines derived from rat and hamster islet cell tumors. <i>Cancer Research</i> , 1991, 51, 1196-201.	0.9	1
179	Molecular and cellular analysis of a neoplastic pancreatic a cell tumor. <i>Cancer</i> , 1990, 65, 1762-1770.	4.1	10
180	Synthesis and secretion of somatostatin-28 and -14 by fetal rat intestinal cells in culture. <i>American Journal of Physiology - Renal Physiology</i> , 1990, 258, G974-G981.	3.4	12

#	ARTICLE	IF	CITATIONS
181	Glucagon and Related Peptides in Fetal Rat Hypothalamus <i>in Vivo</i> and <i>in Vitro</i> .*. <i>Endocrinology</i> , 1990, 126, 110-117.	2.8	43
182	Developmental and Tissue-Specific Regulation of Proglucagon Gene Expression*. <i>Endocrinology</i> , 1990, 127, 2217-2222.	2.8	49
183	Tissue-Specific Differences in the Levels of Proglucagon-Derived Peptides in Streptozotocin-Induced Diabetes*. <i>Endocrinology</i> , 1989, 124, 3003-3009.	2.8	36
184	Proglucagon gene expression is regulated by a cyclic AMP-dependent pathway in rat intestine.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1989, 86, 3953-3957.	7.1	120
185	Control of Glucagon-Like Immunoreactive Peptide Secretion from Fetal Rat Intestinal Cultures*. <i>Endocrinology</i> , 1988, 123, 220-226.	2.8	69
186	Glucagon-Like Immunoreactive Peptides in a Rat Ileal Epithelial Cell Line (IEC-18). <i>Endocrine Research</i> , 1987, 13, 229-241.	1.2	5
187	Fetal Rat Intestinal Cells in Monolayer Culture: A New <i>in Vitro</i> System to Study the Glucagon-Like Immunoreactive Peptides*. <i>Endocrinology</i> , 1987, 120, 1976-1985.	2.8	72
188	Lack of effect of $\hat{1}^2$ -endorphin on basal or glucagon-stimulated hepatic glucose production <i>in vitro</i> . <i>Metabolism: Clinical and Experimental</i> , 1987, 36, 432-437.	3.4	4
189	Ontogeny of glucagon-like immunoreactive peptides in rat intestine. <i>Regulatory Peptides</i> , 1987, 17, 319-326.	1.9	12
190	Beta endorphin modulation of the glucoregulatory effects of repeated epinephrine infusion in alloxan-diabetic and normal dogs. <i>Diabetologia</i> , 1987, 30, 745-754.	6.3	2
191	Hormonal and metabolic responses to intracarotid and intrajugular infusion of $\hat{1}^2$ -endorphin in normal dogs. <i>Canadian Journal of Physiology and Pharmacology</i> , 1986, 64, 306-310.	1.4	6
192	Beta-endorphin modulation of the glucoregulatory effects of repeated epinephrine infusion in normal dogs. <i>Diabetes</i> , 1985, 34, 1293-1300.	0.6	10
193	Human phosphoserine 31 corticotropin1-39. Isolation and characterization. <i>Journal of Biological Chemistry</i> , 1983, 258, 8108-12.	3.4	31
194	Isolation of ACTH1-39, ACTH1-38 and clip from the calf anterior pituitary. <i>Biochemical and Biophysical Research Communications</i> , 1980, 96, 1441-1448.	2.1	28